GSK to Produce One Billion Doses of COVID-19 Vaccine Booster

GlaxoSmithKline plc. (Brentford, UK) plans to manufacture one billion doses of its pandemic vaccine adjuvant system in 2021 to support the development of multiple adjuvanted COVID-19 vaccine candidates.

GSK’s confirmation of its enhanced manufacturing capacity follows completion of a review conducted across the company’s global supply network. GSK has prioritized its efforts towards making its pandemic adjuvant technology available to partners developing promising COVID-19 vaccine candidates that are suitable for use with an adjuvant. To date, the company has formed several collaborations, including with scientific partners in North America, Europe and China, to develop vaccines. The company is also in discussions with governments and global institutions about funding for production and supply of the adjuvant. GSK will manufacture, fill and finish adjuvant for use in COVID-19 vaccines at sites in the UK, US, Canada and Europe.


GSK’s pandemic adjuvant can reduce the amount of vaccine protein required per dose, which allows more vaccine doses to be produced, contributing to protecting more people. Additionally, an adjuvant can enhance the immune response and has been shown to create a stronger and longer-lasting immunity against infections.

“We believe that more than one vaccine will be needed to address this global pandemic and we are working with partners around the world to do so,” said Roger Connor, President, GSK Global Vaccines. “We believe that our innovative pandemic adjuvant technology has the potential to help improve the efficacy and scale up of multiple COVID-19 vaccines. With this significant expansion in our manufacturing capacity, we can help deliver up to 1 billion doses of adjuvanted vaccines through 2021, helping protect many more people and support the global effort to fight COVID-19.”

Related Links:
GlaxoSmithKline plc.